Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FIT Biotech Releases Immunomodulator FIT-06 Study Results
In the study, which was carried out in South Africa, FIT-06 reduced viremia in previously untreated patients. This is expected to be an alternative to antiretroviral therapy (ART)
In the study, which was carried out in South Africa, FIT-06 reduced viremia in previously untreated patients. This is expected to be an alternative to antiretroviral therapy (ART)
Amgen has filed with the FDA in mid of May, the biologics license application (BLA) submission which summarises clinical experience from nearly 6,900 patients across 18 clinical studies,
Reportedly, prior to joining Illumina, Dr Cimler served as president of PandiaDx Consulting, where she provided regulatory and compliance guidance for the development of in vitro diagnostics products
Nitto Denko and Quark Pharma are expected to develop siRNA drugs using Quarkâs RNAi technologies and new structures providing freedom to operate in the siRNA intellectual property space
Fermentas, headquartered in Burlington, Ontario, has approximately 500 employees with principal operations in Vilnius, Lithuania. Thermo Scientific and Fisher Scientific offer a combination of technology development and purchasing
Novo Nordisk has recruited 60,000 patients in the study and is expected to release the results of the multinational study in 2011. Novo Nordisk said that the insulin
Plethora said that hi-Argenol is a novel formulation of purified natural ingredients designed specifically to maintain and improve male sexual health including erectile function and fertility. hi-Argenol is
Medgenics is a commercial-stage biopharmaceutical company, developing tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. Biopumps are made
Abbott said that the findings compared an HIV regimen of its Kaletra and Merck’s Isentress to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors
Clonidine is a centrally acting alpha-agonist hypotensive agent. Mylan has stated that Clonidine stimulates alpha-adrenoreceptors in the brain stem. The action results in reduced sympathetic outflow from the